Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06154837 · ClinicalTrials.gov registry record · Phase 1

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

A Phase 1 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.

Recruiting
Registry status
Phase 1
Development phase
130
Enrollment target
20
Study locations

NCT06154837 is a Phase 1 study of Pulmonary Disease, Chronic Obstructive that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 130 participants, below the 1,042-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06154837, a Phase 1 study of Pulmonary Disease, Chronic Obstructive, is actively recruiting participants, sponsored by GlaxoSmithKline.

RECRUITING
Registry status
Phase 1
Development phase
130 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).

Conditions Studied

Pulmonary Disease, Chronic Obstructive

Interventions

  • DRUG Placebo
  • DRUG GSK3862995B

Study Locations (20)

Other

  • GSK Investigational Site - Ahrensburg
  • GSK Investigational Site - Berlin
  • GSK Investigational Site - Berlin
  • GSK Investigational Site - Berlin
  • GSK Investigational Site - Dresden
  • GSK Investigational Site - Frankfurt
  • GSK Investigational Site - Hamburg
  • GSK Investigational Site - Hamburg
  • GSK Investigational Site - Hanover
  • GSK Investigational Site - Immenhausen
  • GSK Investigational Site - Leipzig

Florida

  • GSK Investigational Site - Hialeah
  • GSK Investigational Site - Plantation

North Carolina

  • GSK Investigational Site - Shelby
  • GSK Investigational Site - Wilmington

Arizona

  • GSK Investigational Site - Yuma

Georgia

  • GSK Investigational Site - Columbus

Oregon

  • GSK Investigational Site - Medford

South Carolina

  • GSK Investigational Site - Rock Hill

Texas

  • GSK Investigational Site - Austin

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2023-11-27
Est. Completion 2027-03-31
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06154837

The ClinicalTrials.gov registry entry for NCT06154837 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,042-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (88% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06154837 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Florida, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06154837 about?

NCT06154837 is a clinical study titled "A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease". The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).

What is the current status of trial NCT06154837?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2023-11-27. Estimated completion is 2027-03-31.

What conditions does trial NCT06154837 study?

This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.

What interventions are being tested in trial NCT06154837?

The interventions under investigation include: Placebo (DRUG), GSK3862995B (DRUG).

Who is sponsoring clinical trial NCT06154837?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06154837 being conducted?

This trial has 20 study locations across Arizona, Florida, Georgia, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Disease, Chronic Obstructive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Disease, Chronic Obstructive

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.